RxDoctor Payments Data

Ashley Blasi, DO

Family Medicine · Savannah, GANPI 1861953085

Payments from drug & device makers

$6,039in general payments, 2019–2025

Across 320 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$931
  • Amgen$670
  • AbbVie$615
  • Lilly USA, LLC$583
  • Pfizer$514
  • AstraZeneca$360
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$6,039100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,039 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$36,101
Medicare patients
101
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$73,966
JardianceEmpagliflozin32$44,680
MounjaroTirzepatide30$40,034
MyrbetriqMirabegron22$15,278
SynthroidLevothyroxine Sodium29$2,329
Atorvastatin Calcium165$1,548
Valsartan46$1,515
Levothyroxine Sodium80$1,442
Albuterol Sulfate HfaAlbuterol Sulfate28$1,433
Rosuvastatin Calcium127$1,263
Duloxetine Hcl47$1,251
Diclofenac Sodium25$1,167
Metoprolol Succinate38$743
Amlodipine Besylate82$647
Fluticasone Propionate44$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$931$73,96660 claims
Boehringer IngelheimJardiance$157$44,68032 claims
Lilly USA, LLCMounjaro$583$40,03430 claims
Astellas Pharma US IncMyrbetriq$185$15,27822 claims
AbbVieSynthroid$615$2,32929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →